Homepage Top Section2

Trazimera has been approved to treat human epidermal growth factor receptor-2 (HER2) overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Pfizer Oncology global president

The committee concluded that Blincyto holds capacity to offer significant clinical benefits, while addition data on cost-effectiveness is required to evaluate its credibility for NHS funding. NICE has

The approval has been granted for Spravato for use in conjunction with an oral antidepressant in adults with TRD, who have cycled through multiple treatments without relief. Janssen

Based in London, Nightstar is engaged in the development and commercialization of one-time treatments for patients with inherited retinal diseases. The company is mainly focused on the development

The regulator has adopted positive opinion and recommended conditional marketing authorization for Lorviqua as monotherapy treatment for adult patients with ALK-positive advanced NSCLC whose disease has progressed after

The clinical trial, which enrolled 41 patients with Parkinson’s Disease, was funded by Parkinson’s UK with support from The Cure Parkinson’s Trust and in association with the North

Danaher seeks to help its customers solve complex challenges and enhance quality of life across the world. GE Biopharma offers instruments, consumables, and software to facilitate research, discovery,

Through the transaction, Ipsen will acquire Clementia’s key late-stage clinical asset palovarotene, which is an investigational retinoic acid receptor gamma (RARγ) selective agonist. Palovarotene is being developed for

As per terms of the deal, Merck’s subsidiary will pay $5.85 per share to purchase all outstanding shares of Immune Design. Immune Design has next-generation in vivo approaches,